{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:12:22Z","timestamp":1778839942227,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clml.2023.08.001","type":"journal-article","created":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T01:20:07Z","timestamp":1691284807000},"page":"e369-e378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyomi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo Montalban","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry A.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly A.","family":"Soltysiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha S.","family":"Tingen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.08.001_bib0001","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2023.08.001_bib0002","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJMsr1905447","article-title":"Epidemiologic signatures in cancer","volume":"381","author":"Welch","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.08.001_bib0003","series-title":"Cancer Facts and figures for African Americans 2019-2021","year":"2019"},{"key":"10.1016\/j.clml.2023.08.001_bib0004","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.1999.17.7.2244","article-title":"Associations between community income and cancer survival in Ontario, Canada, and the United States","volume":"17","author":"Boyd","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.08.001_bib0005","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1001\/archinte.163.18.2135","article-title":"Cancer survival in Kentucky and health insurance coverage","volume":"163","author":"McDavid","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2023.08.001_bib0006","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/jnci\/89.22.1683","article-title":"Breast cancer survival and treatment in health maintenance organization and fee-for-service settings","volume":"89","author":"Potosky","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2023.08.001_bib0007","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/S0277-9536(03)00100-X","article-title":"Does stage at diagnosis influence the observed relationship between socioeconomic status and breast cancer incidence, case-fatality, and mortality?","volume":"57","author":"Yabroff","year":"2003","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.clml.2023.08.001_bib0008","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/BF03404398","article-title":"An international comparison of cancer survival: advantage of Toronto's poor over the near poor of Detroit","volume":"89","author":"Gorey","year":"1998","journal-title":"Can J Public Health"},{"key":"10.1016\/j.clml.2023.08.001_bib0009","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S1047-2797(02)00259-4","article-title":"An international comparison of breast cancer survival: Winnipeg, Manitoba, and Des Moines, Iowa, metropolitan areas","volume":"13","author":"Gorey","year":"2003","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.clml.2023.08.001_bib0010","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1200\/JCO.1991.9.8.1500","article-title":"Socioeconomic status and cancer survival","volume":"9","author":"Cella","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.08.001_bib0011","series-title":"Cancer Facts & Figures 2021","author":"American Cancer","year":"2021"},{"key":"10.1016\/j.clml.2023.08.001_bib0012","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.08.001_bib0013","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjh.13936","article-title":"Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes","volume":"173","author":"Jain","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.08.001_bib0014","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/S2352-3026(15)00021-6","article-title":"Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukemia: retrospective analysis of patient data from five clinical trials","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.08.001_bib0015","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.08.001_bib0016","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.08.001_bib0017","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus imatinib study in treatment-Na\u00efve chronic myeloid leukemia patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.08.001_bib0018","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE Trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.08.001_bib0019","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.08.001_bib0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.29745","article-title":"Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:49:31Z","timestamp":1778838571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2152265023002343"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}